Important caveats of KEYNOTE-045: relevance of these findings in the current and future therapeutic paradigm

Affiliations

Editorial

Julio Slongo et al. Ann Transl Med. 2019 Mar.

. 2019 Mar;7(Suppl 1):S23.

doi: 10.21037/atm.2019.01.81.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R. Vaughn DJ, et al. J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590008 Clinical Trial.

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. 10.3322/caac.21262 - DOI - PubMed
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
1. Davarpanah NN, Yuno A, Trepel JB, et al. Immunotherapy: a new treatment paradigm in bladder cancer. Curr Opin Oncol 2017. [Epub ahead of print]. 10.1097/CCO.0000000000000366 - DOI - PMC - PubMed
1. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009;115:4110-7. 10.1002/cncr.24460 - DOI - PubMed
1. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454-61. 10.1200/JCO.2008.20.5534 - DOI - PubMed